Deprescribing Reveals Potential Strategies for Care Teams
Balancing the potential benefits and harms of medications is an art that Ariel Green has studied for most of her career. Her interest in deprescribing began in 2022 with her work as a research assistant at the Center on Aging and Health and continued during her medical training with Johns Hopkins Medicine.
“I saw more and more examples of times where we were trying to help older adults, but sometimes this led to a cascade of negative downstream consequences for people with multiple conditions, frailty and cognitive impairment,” Green says. This was especially true with medications such as opioids or sleeping pills causing falls or confusion.
During her geriatric medicine fellowship at Johns Hopkins, Green became involved with the American Geriatrics Society’s Choosing Wisely campaign, which raised awareness about medical treatments and tests that may be unnecessary given a patient’s situation and healthcare goals. For people juggling multiple medicines and conditions already, this kind of awareness can have a significant impact. “That got me really interested in [the question of] how we can make these medication decisions more rational and safer and aligned with older adults’ goals for their health,” she says.
Since 2021, Green has led ALIGN: Aligning Medications with What Matters Most, a program that helps pharmacists optimize medications for older adults with dementia and their caregivers according to their care goals. These goals vary but often include things like the ability to dress, play with grandchildren, think clearly, and prevent heart disease. When a patient’s medications are reviewed with their goals in mind, some medications might be cut if their potential harms would likely outweigh their benefits.
“How can we make these medication decisions more rational and safer and aligned with older adults’ goals for their health?”
— Ariel Green
With the help of clinical pharmacists already connected to care teams, the ALIGN team creates educational materials for patients and caregivers, and writes talking points for pharmacists. “The pharmacists use the scripts to try to elicit what matters most specifically relating to medicines, what people’s priorities are, what they feel like medicines are helping or not helping with,” Green says. The team then has the pharmacists offer recommendations for deprescribing to primary care providers (PCPs) based on their patients’ responses. If the PCP agrees, the pharmacist calls the patient and their caregiver to discuss medication changes.
Ariel Green, M.D., M.P.H., Ph.D.The reason for using clinical pharmacists to start this conversation is twofold. First, they’re already embedded in the care team, and second, they have time to have these important conversations with patients and caregivers. “Sending patients or clinicians a brochure about deprescribing — that’s often not enough,” Green says. “But it’s a lot for PCPs [to be having these conversations with patients] as well as all the other things that have to happen during a 15-minute primary care visit.”
Another goal around deprescribing is to get strategies into clinical practice guidelines to help ensure that anyone being treated for a chronic condition can potentially have their list of medicines reviewed. “Deprescribing studies often measure their success as, can we reduce the number of medicines? But we found that, especially for patients with dementia and their care partners, just cutting back on a medicine isn’t necessarily going to help the big picture,” Green says. “Sometimes you have to replace something that you’ve removed with physical therapy or caregiver support or even another medication, but a safer medication.”